Aquestive Therapeutics, Inc. (AQST) Stock AnalysisAQSTStock AnalysisAquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently priced at $5.02, Aquestive Therapeutics shows promising potential for growth, especially with a recent revenue increase of 38% year-over-year in Q2 2026, reaching $13.8 million. The RSI is at 62.66, indicating bullish momentum, while analysts have set a price target of $8, suggesting a potential upside of 59.76%. However, the main risk is the net loss of $22.9 million reported in Q2 2026, which highlights ongoing financial challenges.

4 analysts cover AQST: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.00.